FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103540939> ?p ?o ?g. }

• W2103540939 endingPage "5413" @default.
• W2103540939 startingPage "5404" @default.
• W2103540939 abstract "Abstract Purpose: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer. This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype. Experimental Design: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry. Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant human clear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo. Results: Immunohistochemical analysis showed that mTOR was more frequently activated in clear cell carcinomas than in serous adenocarcinomas (86.6% versus 50%). Treatment with RAD001 markedly inhibited the growth of both RMG1 and KOC7C cells both in vitro and in vivo. Increased expression of phospho-mTOR was observed in cisplatin-resistant RMG1-CR and KOC7C-CR cells, compared with the respective parental cells. This increased expression of phospho-mTOR in cisplatin-resistant cells was associated with increased activation of AKT. RMG1-CR and KOC7C-CR cells showed greater sensitivity to RAD001 than did parental RMG1 and KOC7C cells, respectively, in vitro and in vivo. Conclusion: mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma. Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin. (Clin Cancer Res 2009;15(17):5404–13)" @default.
• W2103540939 created "2016-06-24" @default.
• W2103540939 creator A5006897018 @default.
• W2103540939 creator A5014868247 @default.
• W2103540939 creator A5016917647 @default.
• W2103540939 creator A5018548811 @default.
• W2103540939 creator A5022629155 @default.
• W2103540939 creator A5035890737 @default.
• W2103540939 creator A5054111631 @default.
• W2103540939 creator A5054474479 @default.
• W2103540939 creator A5055405608 @default.
• W2103540939 creator A5060186654 @default.
• W2103540939 creator A5064439691 @default.
• W2103540939 creator A5070591384 @default.
• W2103540939 creator A5090684583 @default.
• W2103540939 date "2009-08-31" @default.
• W2103540939 modified "2023-10-17" @default.
• W2103540939 title "mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary" @default.
• W2103540939 cites W1968049624 @default.
• W2103540939 cites W1968109047 @default.
• W2103540939 cites W1984029678 @default.
• W2103540939 cites W1985046929 @default.
• W2103540939 cites W1986763334 @default.
• W2103540939 cites W2001877789 @default.
• W2103540939 cites W2015062933 @default.
• W2103540939 cites W2021617242 @default.
• W2103540939 cites W2025423482 @default.
• W2103540939 cites W2026569756 @default.
• W2103540939 cites W2028704745 @default.
• W2103540939 cites W2036053898 @default.
• W2103540939 cites W2043103956 @default.
• W2103540939 cites W2045779236 @default.
• W2103540939 cites W2051398284 @default.
• W2103540939 cites W2092440654 @default.
• W2103540939 cites W2102148658 @default.
• W2103540939 cites W2102648794 @default.
• W2103540939 cites W2109528706 @default.
• W2103540939 cites W2117446564 @default.
• W2103540939 cites W2118677643 @default.
• W2103540939 cites W2121117803 @default.
• W2103540939 cites W2126783165 @default.
• W2103540939 cites W2127281537 @default.
• W2103540939 cites W2130941707 @default.
• W2103540939 cites W2137373982 @default.
• W2103540939 cites W2137714688 @default.
• W2103540939 cites W2138391708 @default.
• W2103540939 cites W2142364508 @default.
• W2103540939 cites W2143226867 @default.
• W2103540939 cites W2144724291 @default.
• W2103540939 cites W2147539392 @default.
• W2103540939 cites W2163476499 @default.
• W2103540939 cites W2164895949 @default.
• W2103540939 cites W2168479383 @default.
• W2103540939 cites W2388163742 @default.
• W2103540939 cites W4238454149 @default.
• W2103540939 cites W1995216988 @default.
• W2103540939 doi "https://doi.org/10.1158/1078-0432.ccr-09-0365" @default.
• W2103540939 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2743856" @default.
• W2103540939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19690197" @default.
• W2103540939 hasPublicationYear "2009" @default.
• W2103540939 type Work @default.
• W2103540939 sameAs 2103540939 @default.
• W2103540939 citedByCount "139" @default.
• W2103540939 countsByYear W21035409392012 @default.
• W2103540939 countsByYear W21035409392013 @default.
• W2103540939 countsByYear W21035409392014 @default.
• W2103540939 countsByYear W21035409392015 @default.
• W2103540939 countsByYear W21035409392016 @default.
• W2103540939 countsByYear W21035409392017 @default.
• W2103540939 countsByYear W21035409392018 @default.
• W2103540939 countsByYear W21035409392019 @default.
• W2103540939 countsByYear W21035409392020 @default.
• W2103540939 countsByYear W21035409392021 @default.
• W2103540939 countsByYear W21035409392022 @default.
• W2103540939 countsByYear W21035409392023 @default.
• W2103540939 crossrefType "journal-article" @default.
• W2103540939 hasAuthorship W2103540939A5006897018 @default.
• W2103540939 hasAuthorship W2103540939A5014868247 @default.
• W2103540939 hasAuthorship W2103540939A5016917647 @default.
• W2103540939 hasAuthorship W2103540939A5018548811 @default.
• W2103540939 hasAuthorship W2103540939A5022629155 @default.
• W2103540939 hasAuthorship W2103540939A5035890737 @default.
• W2103540939 hasAuthorship W2103540939A5054111631 @default.
• W2103540939 hasAuthorship W2103540939A5054474479 @default.
• W2103540939 hasAuthorship W2103540939A5055405608 @default.
• W2103540939 hasAuthorship W2103540939A5060186654 @default.
• W2103540939 hasAuthorship W2103540939A5064439691 @default.
• W2103540939 hasAuthorship W2103540939A5070591384 @default.
• W2103540939 hasAuthorship W2103540939A5090684583 @default.
• W2103540939 hasBestOaLocation W21035409391 @default.
• W2103540939 hasConcept C121608353 @default.
• W2103540939 hasConcept C126322002 @default.
• W2103540939 hasConcept C134018914 @default.
• W2103540939 hasConcept C142724271 @default.
• W2103540939 hasConcept C1491633281 @default.
• W2103540939 hasConcept C150173356 @default.
• W2103540939 hasConcept C150903083 @default.
• W2103540939 hasConcept C193270364 @default.

• next